Navigation Links
Cancer Cells May Be Able to Urge Their Own Death
Date:12/22/2010

WEDNESDAY, Dec. 22 (HealthDay News) -- New research suggests that many cancer cells are equipped with a kind of suicide pill: a protein on their surfaces that gives them the ability to send an "eat me" signal to immune cells.

The challenge now, the researchers say, is to figure out how to coax cancer cells into emitting the signal rather than a dangerous "don't eat me" signal.

A study published online Dec. 22 in Science Translational Medicine reports that the cells send out the enticing "eat me" signal by displaying the protein calreticulin. But another molecule, called CD47, allows most cancer cells to avoid destruction by sending the opposite signal: "Don't eat me."

In earlier research, Stanford University School of Medicine scientists found that an antibody that blocks CD47 -- turning off the signal -- could help fight cancer, but mysteries remained.

"Many normal cells in the body have CD47, and yet those cells are not affected by the anti-CD47 antibody," Mark Chao, a Stanford graduate student and the study's lead author, said in a university news release. "At that time, we knew that anti-CD47 antibody treatment selectively killed only cancer cells without being toxic to most normal cells, although we didn't know why."

Now, the new research has shown that calreticulin exists in a variety of cancers, including some types of leukemia, non-Hodgkin's lymphoma and bladder, brain and ovarian cancers. "This research demonstrates that the reason that blocking the CD47 'don't eat me' signal works to kill cancer is that leukemias, lymphomas and many solid tumors also display a calreticulin 'eat me' signal," Dr. Irving Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and a co-principal investigator of the study, said in the release. "The research also shows that most normal cell populations don't display calreticulin and are, therefore, not depleted when we expose them to a blocking anti-CD47 antibody."

The next step is to understand how calreticulin works. "We want to know how it contributes to the disease process and what is happening in the cell that causes the protein to move to the cell surface," Dr. Ravindra Majeti, an assistant professor of hematology and study co-principal investigator, said in the release.

"Any of these mechanisms offer potential new ways to treat the disease by interfering with those processes," Majeti said.

More information

The American Cancer Society has more on cancer.

-- Randy Dotinga

SOURCE: Stanford University School of Medicine, news release, Dec. 22, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
3. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
4. Low forms of cyclin E reduce breast cancer drugs effectiveness
5. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
6. Soft drinks may increase risk of pancreatic cancer
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
9. Single gene mutation induces endometrial cancer
10. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
11. Molecular pathways linked to sex, age affect outcomes in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Cells May Be Able to Urge Their Own Death
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
(Date:2/17/2017)... ... 17, 2017 , ... Qualis Health, one of the nation's ... Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that ... multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... Miami, F.L. (PRWEB) , ... February 17, 2017 ... ... geared to clinical operations executives and focusing on all facets of clinical trial ... portfolio management , patient engagement, and more. In addition, attendees stopping by ...
(Date:2/17/2017)... CO (PRWEB) , ... February 17, 2017 , ... Top ... annual International Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, ... Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting over 60 ...
(Date:2/16/2017)... ... 2017 , ... For some cancer survivors, the memories and ... researchers at The Marcus Institute of Integrative Health at Thomas Jefferson University ... symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 2017 Theravance Biopharma, Inc. (NASDAQ: ... today announced the presentation of positive clinical data ... pan-Janus kinase (JAK) inhibitor designed to be intestinally ... the European Crohn,s and Colitis Organization (ECCO). In ... from its completed Phase 1 study of single-ascending ...
(Date:2/17/2017)... 2017 Research and Markets has announced the addition ... to their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , ... announced a new partnership with Engage , one ... United States . FormFast will serve as the ... Engage,s implementations with MEDITECH .  ... essential functionality to complement and enhance the electronic health ...
Breaking Medicine Technology: